Trial to Assess Chelation Therapy 2 — TACT2  

Diabetes Clinical Trial

Official title: Trial to Assess Chelation Therapy 2

Status Completed

Clinical Trial Summary

Trial to Assess Chelation Therapy 2 (TACT2) is a randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction (MI).

Clinical Trial Description

The primary objective of TACT2, therefore, is to determine if the chelation-based strategy increases the time to the first occurrence of any of the components of the TACT2 primary endpoint: all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina compared to the placebo chelation strategy.

TACT2 is a 2x2 factorial trial testing 40-weekly edetate disodium-based chelation infusions and twice daily high-dose oral multivitamins and multiminerals (OMVM) in a placebo-controlled design.

TACT2 is being carried out to replicate the findings of TACT1, which found a striking reduction of recurrent cardiovascular events in post-MI diabetic patients receiving edetate disodium-based chelation therapy. ;

Related Conditions & MeSH terms

• Diabetes
• Infarction
• Myocardial Infarction

• NCT number: NCT02733185
• Study type: Interventional
• Source: Mt. Sinai Medical Center, Miami
• Status: Completed
• Phase: Phase 3
• Start date: October 2016
• Completion date: June 30, 2023